SecBot SecBot
SECBOTREPLAY Home › Report › EBS

EBS · Emergent BioSolutions announced a $150 million term loan refinancing…

Emergent BioSolutions · PRESS-RELEASE filed Apr 16, 2026 at 16:05 ET

At the news

BEARISHIMPACT 7/10

PRESS-RELEASE filed Apr 16, 2026 at 16:05 ET

Emergent BioSolutions announced a $150 million term loan refinancing with OrbiMed and an amended $50 million ABL facility, extending maturities to April 2031 and reducing interest expense by 200 basis points. The move strengthens liquidity but follows a significant earnings miss.

  • Closed on a new $150 million term loan with OrbiMed, replacing prior debt from Oak Hill Advisors
  • Amended ABL facility with Wells Fargo to extend borrowing capacity of $50 million through April 2031
  • Interest expense reduced by 200 basis points annually
  • Maturities extended from 2029 to 2031 for both facilities

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access